InMed Pharmaceuticals (INM) Short-term Investments (2020 - 2026)

InMed Pharmaceuticals has reported Short-term Investments for 7 years, with the latest figure at $41625.0 in Q1 2026.

• For the quarter ending Q1 2026, Short-term Investments rose 2.57% year-over-year to $41625.0; the trailing twelve-month figure through Mar 2026 stood at $41625.0 (up 2.57% YoY), and the FY2025 full-year result was $43384.0, up 0.74% from the prior year.
• Short-term Investments for Q1 2026 stood at $41625.0, down from $42675.0 in the prior quarter.
• The five-year high for Short-term Investments was $46098.0 in Q1 2022, with the low at $40582.0 in Q1 2025.
• Historically, Short-term Investments has averaged $43072.1 across 5 years, with a median of $43055.0 in 2023.
• Annual changes were most pronounced in 2024 — Short-term Investments fell 8.27% — and 2025, when it advanced 4.63%.
• InMed Pharmaceuticals' Short-term Investments stood at $43053.0 in 2022, then climbed by 3.27% to $44462.0 in 2023, then slipped by 8.27% to $40787.0 in 2024, then advanced by 4.63% to $42675.0 in 2025, then declined by 2.46% to $41625.0 in 2026.
• The last three Short-term Investments figures came in at $41625.0 (Q1 2026), $42675.0 (Q4 2025), and $42859.0 (Q3 2025), per Business Quant data.